In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Drugs for Schistosomiasis market for 2018-2023.
Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.
The global average price of Drugs for Schistosomiasis is in the decreasing trend, from 62 USD/K Units in 2011 to 57 USD/K Units in 2015. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of Drugs for Schistosomiasis is Praziquantel, Oxamniquine and other. Praziquantel is the mainly drug for Schistosomiasis, and the proportion of Praziquantel in 2015 is about 90%.
Drugs for Schistosomiasis are widely used in S. haematobium, S. mansoni, S. japonicum, S. mekongi and S. intercalatum.Most of human infections are caused by S. haematobium, S. mansoni, S. japonicum. And the market share used in S. haematobium in 2015 is 28%. And the market share used in S. mansoni in 2015 is 48%.
Over the next five years, LPI(LP Information) projects that Drugs for Schistosomiasis will register a 5.6% CAGR in terms of revenue, reach US$ 100 million by 2023, from US$ 70 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Schistosomiasis market by product type, application, key manufacturers and key regions.
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Segmentation by application:
This report also splits the market by region:
Middle East & Africa
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Chandra Bhagat Pharma
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
To study and analyze the global Drugs for Schistosomiasis consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Drugs for Schistosomiasis market by identifying its various subsegments.
Focuses on the key global Drugs for Schistosomiasis manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Drugs for Schistosomiasis with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Drugs for Schistosomiasis submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.